RBC Capital raised the firm’s price target on Korro Bio (KRRO) to $105 from $95 and keeps an Outperform rating on the shares. The firm notes that RNA editing data from Wave Life Sciences (WVE) is fantastic news for the broader field, as the bear thesis is officially off the table, also stating that Korro management is impressed by early onset of action, durable effect, and clean safety, the analyst tells investors in a research note. Wave Life Sciences is ahead, but RBC maintains that Korro is the better way to play RNA editing given unconstrained economics, the firm added.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio initiated with a Strong Buy at Raymond James
- Korro Bio price target raised to $115 from $100 at H.C. Wainwright
- Wave Life Sciences price target raised to $20 from $16 at JonesResearch
- Stifel says early WVE-006 data de-risks DNA editing approaches like Beam’s ‘302
- Korro Bio Inc trading resumes